Granlibakken Tahoe Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2015


Here are the related meetings in 2018:
Antimicrobials and Resistance: Opportunities and Challenges (T4)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Gram-Negative Resistance (D1)


Organizer(s) Robert E.W. Hancock and Eric D. Brown
March 29—April 2, 2015
Granlibakken Tahoe • Tahoe City, California USA
Discounted Abstract Deadline: Dec 1, 2014
Abstract Deadline: Jan 6, 2015
Scholarship Deadline: Dec 1, 2014
Discounted Registration Deadline: Jan 27, 2015

Sponsored by Merck & Co., Inc. and Sarepta Therapeutics

Summary of Meeting:
SIGNIFICANCE: The antibiotic era, stemming from the deployment of penicillin, introduced arguably the most successful medicines of all time, impacting dramatically on life expectancy by decreasing childhood and adult deaths from infections, and enabling complex surgeries, transplantations and cancer chemotherapy. However the therapy of infectious diseases is now under severe threat. There has been an explosion of resistance to antibiotics, whereby our entire arsenal of antibiotics is gradually losing effectiveness. This is particularly acute for Gram negative bacteria since there are few new antibiotics or strategies in the development pipeline. In this meeting we will address the major issues and potential solutions to this crisis. INNOVATION: The issues associated with gram-negative resistance, and the design of effective therapeutics, are different and more complicated than those associated with the other major division of bacteria (gram positives). Consistent with the most recent antibiotics are active against the latter class leaving academic and company researchers and physicians to wonder where the next generation of treatments will come from. For this reason, it is essential that these issues are discussed as a distinct problem that has the potential to unravel human medical successes. Here, we will bring together diverse researchers from disciplines ranging from discovery research to drug development and clinical treatment to discuss strategies for addressing this critical issue and proposing routes for innovative solutions.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 29

16:00—20:00
Arrival and Registration

Pre Function
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Granhall
18:00—20:00
Light Meal - Provided by Granlibakken

Granhall

MONDAY, MARCH 30

07:00—08:00
Breakfast

Granhall
08:00—09:00
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
Brad Spellberg, LAC, University of Southern California Medical Center, USA
The Future of Antibiotics and Resistance

09:00—11:15
Gram-Negative Drug Resistance - A Complex Problem
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
* Gerry D. Wright, McMaster University, Canada

José L. Martínez, Centro Nacional de Biotecnologia, CSIC, Spain
The Resistome; Definition, Identification, Tools and Implications

Kim Lewis, Northeastern University, USA
Interplay between Resistance and Tolerance

Diarmaid P. Hughes, Uppsala University, Sweden
Selection of Resistance at Lethal and Non-Lethal Antibiotic Concentrations

Lori L. Burrows, McMaster University, Canada
Short Talk: Agents Provocateur: Stimulation of Biofilm Formation by Bioactive Small Molecules

09:40—10:00
Coffee Break

Pre Function
11:15—13:00
Poster Setup

Bay
13:00—22:00
Poster Viewing

Bay
11:15—17:00
On Own for Lunch

14:30—16:30
Workshop on Structure-Guided Antibiotic Development
Workshop Faculty representing the following centers:
CSGID: Center for Structural Genomics of Infectious Disease
SSGCID: Seattle Structural Genomics Center for Infectious Diseases
DRGN: Structure-­guided drug discovery coalition for drug-­resistant gram-­negative organisms
SGCID: Structural Genomic Centers of Infectious Diseases (CSGID & SSGCID)
ENABLE: The European Gram Negative Anti-Bacterial Engine project within IMI's 'New Drugs for Bad Bugs' (ND4BB) programme
SDDC: Structure-­guided Drug Discovery Coalition for tuberculosis and malaria
MCSG: Midwest Center for Structural Genomics

Mountain/Lake
* Alexei Savchenko, University of Calgary, Canada

Peter J. Myler, Seattle Biomedical Research Institute, USA
Introduction and Overview, including Vision for DRGN

Wayne F. Anderson, Northwestern University Medical School, USA
The SGCISs, Impact on Gram Negatives

Robert Stavenger, GlaxoSmithKline, USA
Current European Collaborative Plans, ENABLE

Gerry D. Wright, McMaster University, Canada
A Model for North American Cooperation in Protein Structure-Function Studies of Antibiotic Resistance

Chris Walpole, SGC, University of Toronto, Canada
The SDDC as a Collaborative Drug Discovery Model

Jane M. Knisely, NIAID, National Institutes of Health, USA
NIAID Resources for Antibacterial Product Development

16:30—17:00
Coffee Available

Pre Function
17:00—19:00
Emerging Threats in Gram-Negative Drug Resistance
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
* Lori L. Burrows, McMaster University, Canada

David M. Livermore, University of East Anglia, UK
Gram-Negatives: A Hydra-Headed Threat

Karen Bush, Indiana University, USA
Updates on Beta-Lactam Resistance in Gram-Negative Pathogens

Jian Li, Monash University, Australia
Polymyxins: Never a Failure, Always a Lesson

Daniel J. Dwyer, University of Maryland, College Park, USA
Short Talk: Targeting Emergent Cell Death Phenomena and Physiological Instability Induced by Antibiotics to Uncover Novel Therapeutic Strategies

19:00—20:00
Dinner

Granhall
19:30—22:00
Poster Session 1

Bay
20:00—21:00
Social Hour
No registration fees are used to fund alcohol served at this function.

Bay

TUESDAY, MARCH 31

07:00—08:00
Breakfast

Granhall
08:00—09:20
Gram-Negative Drug Development - The Future
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
* Karen Bush, Indiana University, USA

Sumathi Nambiar, U.S. Food and Drug Administration, USA
Regulatory Perspective on Drug Development Programs for Gram-Negative Infections

Robert Stavenger, GlaxoSmithKline, USA
IMI Translocation: A PPP Approach to Understanding Gram-Negative Penetration

09:20—09:40
Coffee Break

Pre Function
09:40—11:15
New Approaches in Gram-Negative Small Molecule Drug Discovery
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
* Daniel J. Dwyer, University of Maryland, College Park, USA

Eric D. Brown, McMaster University, Canada
Starving Bacteria to Find New Antibiotics

Dustin T. King, University of British Columbia, Canada

Wright W. Nichols, AstraZeneca R&D Boston, USA
Target-Based Drug Discovery: Where Next?

11:15—13:00
Poster Setup

Bay
13:00—22:00
Poster Viewing

Bay
11:15—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Pre Function
17:00—19:00
Permeability and Efflux
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
* Robert E.W. Hancock, University of British Columbia, Canada

R. Keith Poole, Queen's University, Canada
Multidrug Efflux Systems as Components of Stress Responses in Pseudomonas aeruginosa

Mathias Winterhalter, Jacobs University Bremen, Germany
Quantification of Antibiotic Uptake Across Bacterial Cell Walls

Helen I. Zgurskaya, University of Oklahoma, USA
Multi-Drug Efflux in the Context of Two Membranes

Thien-Fah Mah, University of Ottawa, Canada
Short Talk: Identification of a Novel Transcriptional Regulator of Antibiotic Resistance in Pseudomonas aeruginosa

19:00—20:00
Dinner

Granhall
19:30—22:00
Poster Session 2

Bay
20:00—21:00
Social Hour
No registration fees are used to fund alcohol served at this function.

Bay

WEDNESDAY, APRIL 1

07:00—08:00
Breakfast

Granhall
08:00—11:00
Alternatives to Small Molecule Antibiotics - Targeting the Host
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
* Helen I. Zgurskaya, University of Oklahoma, USA

Robert E.W. Hancock, University of British Columbia, Canada
Targeting the Host

Laurence Rahme, Massachusetts General Hospital, USA
Anti-Virulence Approaches against Acute and Persistent/Relapsing Pseudomonas aeruginosa Infections

Charles Ken Stover, MedImmune, LLC, USA
Targeting Serious Bacterial Infections with New Antibody-Based Strategies

David A. Putnam, Cornell University, USA
Recombinant Bacterial Outer Membrane Vesicles for Subunit Vaccine Modulation

Andrew Nelson Gray, University of California, San Francisco, USA
Short Talk: The Careful Coordination of Envelope Constriction Processes Required for Maintaining Cell Integrity Are Points of Vulnerability Susceptible to Disruption

09:20—09:40
Coffee Break

Pre Function
11:00—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Pre Function
17:00—18:45
Natural Products – Time for a Comeback
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
* Eric D. Brown, McMaster University, Canada

Adam C. Palmer, Harvard Medical School, USA
Evolutionary Insights into Antibiotic Mechanisms

Gerry D. Wright, McMaster University, Canada
Natural Products to Reverse Drug Resistance in Gram Negative Pathogens

Roger G. Linington, , USA
Activity Profile Screening: High Content Screening Approaches to Natural Product Antibiotic Discovery

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
19:00—20:00
Dinner

Granhall
19:00—20:00
Social Hour
No registration fees are used to fund alcohol served at this function.

Granhall
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Granhall

THURSDAY, APRIL 2

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Merck & Co., Inc. Sarepta Therapeutics

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI115778-01

Funding for this conference was made possible [in part] by 1 R13 AI 115778-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



AstraZeneca Pharmaceuticals, L.P.


MedImmune


Pfizer Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Center for Structural Genomics of Infectious Diseases


Seattle Structural Genomics Center for Infectious Disease


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676